DOCSLIB.ORG

Realtime Ready Human Apoptosis Panel

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Realtime Ready Human Apoptosis Panel For life science research only. FOR IN VITRO USE ONLY. Human Apoptosis Panel, 384 Ready-to-use panel for the gene expression profiling of apoptosis-related genes Cat. No. 05 339 316 001 2 plates, each containing 384 assays Version November 2008 N Store at +2 to +8°C N Store protected from light! Plate Layout 123456789101112131415161718192021222324 A 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 B 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 C 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 D 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 E 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 F 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 G 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 H 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 I 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 J 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 K 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 L 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 M 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 N 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 O 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 P 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 P13 – P19: Reference genes P20 – P22: RT positive control P23 – P24: RT minus control Sample Details No. Pos HGNC- Description No. Pos HGNC- Description Symbol Symbol 1 A 01 AATF Protein AATF 16 A 16 AVEN Cell death regulator Aven. 2 A 02 ABL1 Proto-oncogene tyrosine-protein kinase ABL1 17 A 17 AZU1 Azurocidin precursor 3 A 03 ACVR1B Activin receptor type-1B precursor 18 A 18 BAD Bcl2 antagonist of cell death 4 A 04 ADORA1 Adenosine receptor A1. 19 A 19 BAG1 BAG family molecular chaperone regulator 1 5 A 05 AIFM1 Apoptosis-inducing factor 1, mitochondrial precursor 20 A 20 BAG3 BAG family molecular chaperone regulator 3 6 A 06 AIFM2 Apoptosis-inducing factor 2 21 A 21 BAG4 BAG family molecular chaperone regulator 4 7 A 07 AIFM3 Apoptosis-inducing factor 3 22 A 22 BAK1 Bcl-2 homologous antagonist/killer 8 A 08 AKT1 Proline-rich AKT1 substrate 1 23 A 23 BAX Apoptosis regulator BAX. 9 A 09 ALOX15B Arachidonate 15-lipoxygenase type II 24 A 24 BBC3 Bcl-2-binding component 3 10 A 10 ANXA1 Annexin A1 25 B 01 BCAP31 B-cell receptor-associated protein 31 11 A 11 ANXA4 Annexin A4 26 B 02 BCL10 B-cell lymphoma/leukemia 10 12 A 12 APAF1 Apoptotic protease-activating factor 1 27 B 03 BCL2 Apoptosis regulator Bcl-2. 13 A 13 API5 Apoptosis inhibitor 5 28 B 04 BCL2A1 Bcl-2-related protein A1 14 A 14 APOE Apolipoprotein E precursor 29 B 05 BCL2L1 Apoptosis regulator Bcl-X 15 A 15 ATF5 Cyclic AMP-dependent transcription factor ATF-5 30 B 06 BCL2L10 Apoptosis regulator Bcl-B www.roche-applied-science.com No. Pos HGNC- Description No. Pos HGNC- Description Symbol Symbol 31 B 07 BCL2L11 Bcl-2-like protein 11 84 D 12 CD38 ADP-ribosyl cyclase 1 32 B 08 BCL2L13 Bcl-2-like 13 protein 85 D 13 CD40 Tumor necrosis factor receptor superfamily member 5 precursor 33 B 09 BCL2L2 Apoptosis regulator Bcl-W 86 D 14 CD40LG CD40 ligand 34 B 10 BCL3 B-cell lymphoma 3-encoded protein 87 D 15 CD5 T-cell surface glycoprotein CD5 precursor 35 B 11 BCL6 B-cell lymphoma 6 protein 88 D 16 CD70 CD70 antigen 36 B 12 BCLAF1 Bcl-2-associated transcription factor 1 89 D 17 CDKN1A Cyclin-dependent kinase inhibitor 1 (p21) 37 B 13 BDNF Brain-derived neurotrophic factor precursor 90 D 18 CEBPB CCAAT/enhancer-binding protein beta 38 B 14 BECN1 Beclin-1 91 D 19 CEBPG CCAAT/enhancer-binding protein gamma 39 B 15 BFAR Bifunctional apoptosis regulator 92 D 20 CFDP1 Craniofacial development protein 1 40 B 16 BID BH3-interacting domain death agonist 93 D 21 CFL1 Cofilin-1 41 B 17 BIK Bcl-2-interacting killer 94 D 22 CFLAR CASP8 and FADD-like apoptosis regulator precursor 42 B 18 BIRC2 Baculoviral IAP repeat-containing protein 2 95 D 23 CHEK2 Serine/threonine-protein kinase Chk2 43 B 19 BIRC3 Baculoviral IAP repeat-containing protein 3 96 D 24 CHUK Inhibitor of nuclear factor kappa-B kinase subunit 44 B 20 BIRC5 Baculoviral IAP repeat-containing protein 5 alpha 45 B 21 BIRC6 Baculoviral IAP repeat-containing protein 6 97 E 01 CIDEA Cell death activator CIDE-A 46 B 22 BIRC7 Baculoviral IAP repeat-containing protein 7 98 E 02 CIDEB Cell death activator CIDE-B 47 B 23 BIRC8 Baculoviral IAP repeat-containing protein 8 99 E 03 CIDEC Cell death activator CIDE-3 48 B 24 BMF Bcl-2-modifying factor. 100 E 04 COL4A3 Collagen alpha-3 49 C 01 BNIP1 Vesicle transport protein SEC20 101 E 05 CRADD Death domain-containing protein CRADD 50 C 02 BNIP2 BCL2/adenovirus E1B 19 kDa protein-interacting pro- 102 E 06 CRYAA Alpha-crystallin A chain tein 2. 103 E 07 CRYAB Alpha-crystallin B chain 51 C 03 BNIP3 BCL2/adenovirus E1B 19 kDa protein-interacting pro- tein 3. 104 E 08 CUL1 Cullin-1 52 C 04 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like 105 E 09 CUL2 Cullin-2 53 C 05 BOK Bcl-2-related ovarian killer protein 106 E 10 CUL3 Cullin-3 54 C 06 BRAF B-Raf proto-oncogene serine/threonine-protein 107 E 11 CUL4A Cullin-4A kinase 108 E 12 CUL5 Cullin-5 55 C 07 BRCA1 Breast cancer type 1 susceptibility protein 109 E 13 CYCS Cytochrome c 56 C 08 BRE Protein BRE 110 E 14 DAD1 Dolichyl-diphosphooligosaccharide--protein glycosyl- 57 C 09 BTK Tyrosine-protein kinase BTK transferase subunit DAD1 58 C 10 CAD CAD protein 111 E 15 DAP Death-associated protein 1 59 C 11 CARD10 Caspase recruitment domain-containing protein 10 112 E 16 DAP3 Death associated protein 3 60 C 12 CARD11 Caspase recruitment domain-containing protein 11 113 E 17 DAPK1 Death-associated protein kinase 1. 61 C 13 CARD14 Caspase recruitment domain-containing protein 14 114 E 18 DAPK2 Death-associated protein kinase 2 62 C 14 CARD4 Nucleotide-binding oligomerization domain-contain- 115 E 19 DAPK3 Death-associated protein kinase 3 ing protein 1 116 E 20 DAXX Death domain-associated protein 6 63 C 15 CARD6 Caspase recruitment domain-containing protein 6. 117 E 21 DBP D site-binding protein 64 C 16 CARD8 Caspase recruitment domain-containing protein 8 118 E 22 DCC Netrin receptor DCC precursor 65 C 17 CARD9 Caspase recruitment domain-containing protein 9 119 E 23 DDAH2 dimethylarginine dimethylaminohydrolase 2 66 C 18 CASP1 Caspase-1 precursor 120 E 24 DDIT3 DNA damage-inducible transcript 3 67 C 19 CASP10 Caspase-10 precursor 121 F 01 DDX20 Probable ATP-dependent RNA helicase DDX20 68 C 20 CASP12 Inactive caspase-12 122 F 02 DEDD Death effector domain-containing protein 69 C 21 CASP14 Caspase-14 precursor 123 F 03 DEDD2 DNA-binding death effector domain-containing pro- 70 C 22 CASP2 Caspase-2 precursor tein 2 71 C 23 CASP3 Caspase-3 precursor 124 F 04 DFFA DNA fragmentation factor subunit alpha 72 C 24 CASP4 Caspase-4 precursor 125 F 05 DHCR24 24-dehydrocholesterol reductase precursor 73 D 01 CASP5 Caspase-5 precursor 126 F 06 DIABLO Diablo homolog, mitochondrial precursor 74 D 02 CASP6 Caspase-6 precursor 127 F 07 DPF2 Zinc finger protein ubi-d4 75 D 03 CASP7 Caspase-7 precursor 128 F 08 DYRK2 Dual specificity tyrosine-phosphorylation-regulated kinase 1A 76 D 04 CASP8 Caspase-8 precursor 129 F 09 EDA Ectodysplasin A 77 D 05 CASP8AP2 CASP8-associated protein 2 130 F 10 EDAR Ectodysplasin A receptor 78 D 06 CASP9 Caspase-9 precursor 131 F 11 EEF1A2 Elongation factor 1-alpha 2 79 D 07 CBX4 E3 SUMO-protein ligase CBX4 132 F 12 EIF2AK3 Eukaryotic translation initiation factor 2-alpha kinase 3 80 D 08 CCL2 C-C motif chemokine 2 precursor precursor 81 D 09 CD2 CD2 molecule 133 F 13 endoG Endonuclease G, mitochondrial precursor 82 D 10 CD27 CD27 antigen precursor 134 F 14 ERC1 ELKS/RAB6-interacting/CAST family member 1 83 D 11 CD28 T-cell-specific surface glycoprotein CD28 precursor 2 www.roche-applied-science.com No.
Load more

Recommended publications
  • University of Milano-Bicocca Department of Medicine and Surgery Circulating Levels of Soluble Receptor for Advanced Glycation En
    University of Milano-Bicocca Department of medicine and surgery PhD PROGRAM IN TRANSLATIONAL AND MOLECULAR MEDICINE DIMET Circulating levels of soluble Receptor for Advanced Glycation End-products (sRAGE) decrease with aging and may predict age- related cardiac remodeling Coordinator: Prof. Andrea Biondi Tutor: Prof. Giulio Pompilio Co-tutor: Dr. Angela Raucci Dr. Filippo Zeni Matr N°: 787963 XXIX CYCLE Academic Year 2015-2016 Table of contents Chapter 1……………..……………………………………………………………….3 General Introduction ............................................................................. 4 Aging ............................................................................................................ 4 Molecular mechanisms of aging ................................................................ 5 DNA Damage and instability .............................................................................. 5 DNA damage and apoptosis ............................................................................... 6 Telomere shortening ............................................................................................. 7 Epigenetic Alterations .......................................................................................... 8 Mitochondrial dysfunction .............................................................................. 10 Stem cells exhaustion ......................................................................................... 11 Biomarkers of aging ..........................................................................................
    [Show full text]
  • RT² Profiler PCR Array (384-Well Format) Human Apoptosis 384HT
    RT² Profiler PCR Array (384-Well Format) Human Apoptosis 384HT Cat. no. 330231 PAHS-3012ZE For pathway expression analysis Format For use with the following real-time cyclers RT² Profiler PCR Array, Applied Biosystems® models 7900HT (384-well block), Format E ViiA™ 7 (384-well block); Bio-Rad CFX384™ RT² Profiler PCR Array, Roche® LightCycler® 480 (384-well block) Format G Description The Human Apoptosis RT² Profiler PCR Array profiles the expression of 370 key genes involved in apoptosis, or programmed cell death. The array includes the TNF ligands and their receptors; members of the bcl-2 family, BIR (baculoviral IAP repeat) domain proteins, CARD domain (caspase recruitment domain) proteins, death domain proteins, TRAF (TNF receptor-associated factor) domain proteins and caspases. These 370 genes are also grouped by their functional contribution to apoptosis, either anti-apoptosis or induction of apoptosis. Using real-time PCR, you can easily and reliably analyze expression of a focused panel of genes related to apoptosis with this array. For further details, consult the RT² Profiler PCR Array Handbook. Sample & Assay Technologies Shipping and storage RT² Profiler PCR Arrays in formats E and G are shipped at ambient temperature, on dry ice, or blue ice packs depending on destination and accompanying products. For long term storage, keep plates at –20°C. Note: Ensure that you have the correct RT² Profiler PCR Array format for your real-time cycler (see table above). Note: Open the package and store the products appropriately immediately
    [Show full text]
  • Genome-Wide Analysis of Host-Chromosome Binding Sites For
    Lu et al. Virology Journal 2010, 7:262 http://www.virologyj.com/content/7/1/262 RESEARCH Open Access Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1) Fang Lu1, Priyankara Wikramasinghe1, Julie Norseen1,2, Kevin Tsai1, Pu Wang1, Louise Showe1, Ramana V Davuluri1, Paul M Lieberman1* Abstract The Epstein-Barr Virus (EBV) Nuclear Antigen 1 (EBNA1) protein is required for the establishment of EBV latent infection in proliferating B-lymphocytes. EBNA1 is a multifunctional DNA-binding protein that stimulates DNA replication at the viral origin of plasmid replication (OriP), regulates transcription of viral and cellular genes, and tethers the viral episome to the cellular chromosome. EBNA1 also provides a survival function to B-lymphocytes, potentially through its ability to alter cellular gene expression. To better understand these various functions of EBNA1, we performed a genome-wide analysis of the viral and cellular DNA sites associated with EBNA1 protein in a latently infected Burkitt lymphoma B-cell line. Chromatin-immunoprecipitation (ChIP) combined with massively parallel deep-sequencing (ChIP-Seq) was used to identify cellular sites bound by EBNA1. Sites identified by ChIP- Seq were validated by conventional real-time PCR, and ChIP-Seq provided quantitative, high-resolution detection of the known EBNA1 binding sites on the EBV genome at OriP and Qp. We identified at least one cluster of unusually high-affinity EBNA1 binding sites on chromosome 11, between the divergent FAM55 D and FAM55B genes. A con- sensus for all cellular EBNA1 binding sites is distinct from those derived from the known viral binding sites, sug- gesting that some of these sites are indirectly bound by EBNA1.
    [Show full text]
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • Human CD27 / TNFRSF7 Protein, His Tag (MALS Verified) Catalog # CD7-H522b
    Human CD27 / TNFRSF7 Protein, His Tag (MALS Verified) Catalog # CD7-H522b Synonym Formulation CD27,TNFRSF7,S152,T14,Tp55 Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is Source added as protectant before lyophilization. Human CD27, His Tag (CD7-H522b) is expressed from human 293 cells Contact us for customized product form or formulation. (HEK293). It contains AA Thr 21 - Ile 192 (Accession # P26842-1). Reconstitution Predicted N-terminus: Thr 21 Molecular Characterization Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA. Storage This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 21.1 kDa. The protein migrates as 35-45 For long term storage, the product should be stored at lyophilized state at -20°C kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. or lower. Please avoid repeated freeze-thaw cycles. Endotoxin This product is stable after storage at: Less than 1.0 EU per μg by the LAL method. -20°C to -70°C for 12 months in lyophilized state; ° Purity -70 C for 3 months under sterile conditions after reconstitution. >90% as determined by SDS-PAGE. SDS-PAGE SEC-MALS Human CD27, His Tag on SDS-PAGE under reducing (R) condition. The gel The purity of Human CD27, His Tag (Cat. No. CD7-H522b) was more than was stained overnight with Coomassie Blue. The purity of the protein is greater 85% and the molecular weight of this protein is around 38-48 kDa verified by than 90%.
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Mutations in EDA and EDAR Genes in a Large Mexican Hispanic Cohort with Hypohidrotic Ectodermal Dysplasia
    Letter to the Editor http://dx.doi.org/10.5021/ad.2015.27.4.474 Mutations in EDA and EDAR Genes in a Large Mexican Hispanic Cohort with Hypohidrotic Ectodermal Dysplasia Julio C Salas-Alanis1,2, Eva Wozniak3, Charles A Mein3, Carola C Duran Mckinster4, Jorge Ocampo-Candiani1, David P Kelsell5, Rong Hua6, Maria L Garza-Rodriguez7, Keith A Choate6, Hugo A Barrera Saldaña7,8 1Dermatology Department, Hospital Universitario, Universidad Autonoma de Nuevo Leon, 2Basic Science Department, Medicine School, Universidad de Monterrey, Monterrey, NL, Mexico, 3Barts and the London Genome Centre, John Vane Science Centre, Barts and the London School of Medicine and Dentistry, University of London, London, United Kingdom, 4Instituto Nacional de Pediatria, Coyoacan, CP, Mexico, 5Centre for Cutaneous Research, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, 6Departments of Dermatology, Genetics, and Pathology, Yale University School of Medicine, New Haven, CT, USA, 7Facultad de Medicina, Departamento de Bioquímica y Medicina Molecular, Universidad Autonoma de Nuevo Leon,8Vitagenesis, Monterrey, NL, Mexico Dear Editor: cludes dryness of the skin, eyes, airways, and mucous Ectodermal dysplasias (ED) encompass nearly 200 differ- membranes, as well as other ectodermal defects and, in ent genetic conditions identified by the lack, or dysgenesis, some cases, fever, seizures, and rarely, death. of at least two ectodermal derivatives, such as hair, nails, XL-HED is caused by mutations in the EDA gene, located teeth, and sweat glands. Hypohidrotic/anhidrotic ED (HED) on chromosome Xq12-q13.1, which encodes a signaling is the most frequent form of ED and it can be inherited as molecule of the tumor necrosis factor (TNF) superfamily.
    [Show full text]
  • Functional Analysis of Ectodysplasin-A Mutations in X-Linked Non-Syndromic Hypodontia and Possible Involvement of X-Chromosome Inactivation
    Functional analysis of Ectodysplasin-A mutations in X-linked non-syndromic hypodontia and possible involvement of X-chromosome inactivation Yuhua Pan ( [email protected] ) Southern Medical University https://orcid.org/0000-0001-8039-1627 Ting Lu Southern Medical University Ling Peng Southern Medical University Qi Zeng Southern Medical University Xiangyu Huang Southern Medical University Buling Wu Southern Medical University Fu Xiong Southern Medical University Research Article Keywords: ectodysplasin-A, dental pulp stem cells, X chromosome inactivation, tooth agenesis, odontogenic differentiation Posted Date: August 13th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-602940/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/17 Abstract Background: Mutations of the Ectodysplasin-A (EDA) gene are generally associated with syndrome hypohidrotic ectodermal dysplasia or non-syndromic tooth agenesis. The inuence of EDA mutations on dentinogenesis and odontoblast differentiation have not been reported. The aim of this study was to identify genetic clues for the causes of familial non-syndromic oligodontia and explore the underlying mechanisms involved, while focusing on the role of human dental pulp stem cells (hDPSCs). Materials and Methods: Candidate gene sequences were obtained by PCR amplication and Sanger sequencing. Functional analysis was conducted, and the pathogenesis associated with EDA mutations in hDPSCs was investigated to explore the impact of the identied mutation on the phenotype. Capillary electrophoresis (CE) was used to detect X chromosome inactivation (XCI) in the blood of female carriers. Results: In this study, we identied an EDA mutation in a Chinese familythe missense mutation c.1013C>T (Thr338Met).
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • Molecular Effects of Isoflavone Supplementation Human Intervention Studies and Quantitative Models for Risk Assessment
    Molecular effects of isoflavone supplementation Human intervention studies and quantitative models for risk assessment Vera van der Velpen Thesis committee Promotors Prof. Dr Pieter van ‘t Veer Professor of Nutritional Epidemiology Wageningen University Prof. Dr Evert G. Schouten Emeritus Professor of Epidemiology and Prevention Wageningen University Co-promotors Dr Anouk Geelen Assistant professor, Division of Human Nutrition Wageningen University Dr Lydia A. Afman Assistant professor, Division of Human Nutrition Wageningen University Other members Prof. Dr Jaap Keijer, Wageningen University Dr Hubert P.J.M. Noteborn, Netherlands Food en Consumer Product Safety Authority Prof. Dr Yvonne T. van der Schouw, UMC Utrecht Dr Wendy L. Hall, King’s College London This research was conducted under the auspices of the Graduate School VLAG (Advanced studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences). Molecular effects of isoflavone supplementation Human intervention studies and quantitative models for risk assessment Vera van der Velpen Thesis submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Friday 20 June 2014 at 13.30 p.m. in the Aula. Vera van der Velpen Molecular effects of isoflavone supplementation: Human intervention studies and quantitative models for risk assessment 154 pages PhD thesis, Wageningen University, Wageningen, NL (2014) With references, with summaries in Dutch and English ISBN: 978-94-6173-952-0 ABSTRact Background: Risk assessment can potentially be improved by closely linked experiments in the disciplines of epidemiology and toxicology.
    [Show full text]
  • Antigen-Specific Memory CD4 T Cells Coordinated Changes in DNA
    Downloaded from http://www.jimmunol.org/ by guest on September 24, 2021 is online at: average * The Journal of Immunology The Journal of Immunology published online 18 March 2013 from submission to initial decision 4 weeks from acceptance to publication http://www.jimmunol.org/content/early/2013/03/17/jimmun ol.1202267 Coordinated Changes in DNA Methylation in Antigen-Specific Memory CD4 T Cells Shin-ichi Hashimoto, Katsumi Ogoshi, Atsushi Sasaki, Jun Abe, Wei Qu, Yoichiro Nakatani, Budrul Ahsan, Kenshiro Oshima, Francis H. W. Shand, Akio Ametani, Yutaka Suzuki, Shuichi Kaneko, Takashi Wada, Masahira Hattori, Sumio Sugano, Shinichi Morishita and Kouji Matsushima J Immunol Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Author Choice option Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Freely available online through http://www.jimmunol.org/content/suppl/2013/03/18/jimmunol.120226 7.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Author Choice Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 24, 2021. Published March 18, 2013, doi:10.4049/jimmunol.1202267 The Journal of Immunology Coordinated Changes in DNA Methylation in Antigen-Specific Memory CD4 T Cells Shin-ichi Hashimoto,*,†,‡ Katsumi Ogoshi,* Atsushi Sasaki,† Jun Abe,* Wei Qu,† Yoichiro Nakatani,† Budrul Ahsan,x Kenshiro Oshima,† Francis H.
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]